You just read:

Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging

News provided by

Genomic Health, Inc.

Nov 30, 2017, 07:00 ET